Latest Innovation News

HITIQ Limited has successfully closed its shortfall offer, raising a total of $2.16 million through a combination of a rights issue and placement, while continuing discussions to secure additional funding.

Neurizon Therapeutics faces a delay in FDA review for its lead ALS therapy NUZ-001, with a new decision expected by early October amid agency-wide staffing challenges.

Mirvac Group reported a solid FY25 with $736 million EBIT and expanded its Build-to-Rent portfolio, while guiding for EPS growth in FY26 amid a supportive market backdrop.

EMVision Medical Devices has been awarded a $3 million non-dilutive government grant to conduct a pioneering clinical study using its telehealth-enabled emu™ brain scanner in regional South Australia, aiming to transform stroke diagnosis and treatment.

Amcor has completed its transformative acquisition of Berry Global, reporting a 43% jump in quarterly net sales and projecting strong earnings growth for fiscal 2026. The company’s strategic portfolio review and synergy realisation efforts underpin an optimistic outlook.

Baby Bunting delivered a standout FY25 with pro forma NPAT soaring 228% to $12.1 million, driven by record sales and a successful store refurbishment program. The retailer’s growth strategy is gaining momentum as it plans an aggressive rollout of its ‘Store of the Future’ concept.

Baby Bunting Group Limited reported a remarkable 462% increase in statutory net profit after tax for FY2025, driven by strong sales growth and strategic store refurbishments. The company also advanced its sustainability initiatives and expanded its digital and retail media businesses.

Cochlear Limited reported a solid FY25 with 4% revenue growth and a 1% rise in underlying profit, underpinned by new product launches and expanding evidence linking implants to reduced dementia risk. The company’s FY26 outlook signals further gains as it advances market leadership and innovation.

Cochlear Limited reported a 4% revenue rise in FY25, driven by strong implant sales and launched the world’s first smart cochlear implant system. The company forecasts up to 17% profit growth in FY26, underpinned by innovation and expanding markets.

Cochlear Limited has announced a fully franked ordinary dividend of AUD 2.15 per share for the six months ending June 2025, payable in October with multi-currency options for shareholders.

Cochlear Limited has reported steady financial growth with a 4% rise in sales revenue and a 9% increase in underlying net profit for the fiscal year ending June 2025, maintaining its dividend payout.

Phoslock Environmental Technologies prepares for ASX reinstatement with improved sales, factory refurbishment, and ongoing legal mediation.